Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
Charles Archer
Oct 15, 2025
Immupharma.
The Immunormalizer: How a Small British Biotech Might Have Cracked the Autoimmune Code.
To read the full article
click here
←
Previous:
Appointment of Independent Non-Executive Director
Next:
Launch of New Website & Corporate Update
→
